中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

38 records (took 0.022 seconds)

    Pressure sensitive adhesive matrix patch for the treatment of onychomycosis
    5.
    发明授权
    Pressure sensitive adhesive matrix patch for the treatment of onychomycosis 失效
    压敏胶基质贴剂用于治疗甲真菌病

    公开(公告)号：US06727401B1

    公开(公告)日：2004-04-27

    申请号：US09022504

    申请日：1998-02-12

    Applicant: Srinivasan Venkateshwaran ,  Danyi Quan

    Inventor： Srinivasan Venkateshwaran ,  Danyi Quan

    IPC: A61F1300

    CPC classification number: A61K9/7061 ,  A61F13/105 ,  A61K8/4946 ,  A61Q3/00

    Abstract: A device for treating antifungal infections of toenails and fingernails is made up of an occlusive backing layer and a pressure sensitive adhesive matrix layer in which is uniformly dispersed an effective amount of an antifungal agent and, optionally, a chemical enhancer. The matrix layer has a first surface adhering to the backing layer and a second surface adapted to be in diffusional contact with the infected nail and surrounding skin area. The device is configured, when applied, to cover and adhere to the nail and surrounding skin areas for an extended period of time without causing irritation to the skin or inhibiting normal physical activity while providing a continuous delivery of antifungal agent to the infected area.

    Abstract translation: 用于治疗脚趾甲和指甲的真菌感染的装置由闭塞背衬层和压敏粘合剂基质层组成，其中均匀分散有效量的抗真菌剂和任选的化学增强剂。 基质层具有粘附到背衬层的第一表面和适于与受感染的指甲和周围皮肤区域扩散接触的第二表面。 该装置在施用时被配置为在延长的时间段内覆盖并粘附到指甲和周围皮肤区域，而不会对皮肤产生刺激或抑制正常的身体活动，同时提供抗真菌剂到感染区域的连续递送。

    Drug delivery compositions for improved stability of steroids
    6.
    发明授权
    Drug delivery compositions for improved stability of steroids 失效
    用于改善类固醇稳定性的药物输送组合物

    公开(公告)号：US5780050A

    公开(公告)日：1998-07-14

    申请号：US504430

    申请日：1995-07-20

    Applicant: Uday Jain ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

    Inventor： Uday Jain ,  Srinivasan Venkateshwaran ,  Charles D. Ebert

    IPC: A61K9/70 ,  A61K31/565 ,  A61K31/57 ,  A61K47/04 ,  A61K47/10 ,  A61K47/14 ,  A61K47/16 ,  A61K47/20 ,  A61K47/30 ,  A61K47/32 ,  A61K47/44 ,  A61P5/24 ,  A61P5/38 ,  A61F13/00

    CPC classification number: A61K9/7061 ,  A61K31/568 ,  A61K31/569 ,  A61K31/57 ,  A61K31/573 ,  A61K31/575

    Abstract: A stabilized patch device for transdermal drug delivery of steroid drugs containing a 3-keto-4-en functional group is described, wherein the patch comprises an effective amount of the steroid drug and a carrier that is free of acid functional groups. The device can further contain additives such as a penetration enhancer or excipient, so long as such additives are also free of acid functional groups. The device can be either a matrix patch or a liquid reservoir patch. In a matrix patch, the carrier is a biocompatible polymeric adhesive with which the steroid drug is intimately admixed. The adhesive is preferably an acrylic polymer or copolymer. In a liquid reservoir patch, the carrier is a controlled-viscosity composition containing a thinner or thickener. Preferred steroid drugs include certain corticosteroids and sex hormones, such as progestins and androgens. A method of stabilizing such steroid drugs during storage in transdermal patches is also disclosed.

    Abstract translation: 描述了一种用于经皮药物递送含有3-酮-4-烯官能团的类固醇药物的稳定补片装置，其中补片包含有效量的类固醇药物和不含酸官能团的载体。 该装置可以进一步含有添加剂如渗透促进剂或赋形剂，只要这些添加剂也不含酸官能团。 该装置可以是矩阵补丁或液体储存器补丁。 在基质贴剂中，载体是与类固醇药物紧密混合的生物相容的聚合物粘合剂。 粘合剂优选为丙烯酸类聚合物或共聚物。 在液体储存贴片中，载体是含有较薄或增稠剂的受控粘度组合物。 优选的类固醇药物包括某些皮质类固醇和性激素，如孕激素和雄激素。 还公开了在透皮贴剂储存期间稳定这种类固醇药物的方法。

    Progesterone Containing Oral Dosage Forms and Related Methods
    9.
    发明申请
    Progesterone Containing Oral Dosage Forms and Related Methods 审中-公开
    孕激素含有口服剂型及相关方法

    公开(公告)号：US20110312928A1

    公开(公告)日：2011-12-22

    申请号：US13204562

    申请日：2011-08-05

    Applicant: Satish Kumar Nachaegari ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

    Inventor： Satish Kumar Nachaegari ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Mahesh V. Patel ,  Srinivasan Venkateshwaran

    IPC: A61K31/57 ,  A61P15/00 ,  A61P15/18 ,  A61P15/16 ,  A61P35/00 ,  A61P19/10

    CPC classification number: A61K31/57 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/209 ,  A61K9/2846 ,  A61K9/4808 ,  A61K9/4858 ,  A61K9/4866

    Abstract: The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood plasma level, after administration of single dose of progesterone composition, such that the ratio of pregnane metabolite level to parent progesterone level of less than 10:1; has a dissolution rate in vitro, when measure using a USP Type-1 dissolution apparatus in 900 mL of deionized water with 2.0% (w/v) of sodium lauryl sulfate at 100 rpm, such that the oral dosage form releases at least 10 wt % of the progesterone within the first 30 minutes and/or releases less than 45 wt % in the first 4 hours; and the oral dosage form produces a ratio of mean plasma progesterone AUC to the amount of progesterone administered of more than 1.5×10−6 hr/mL:1.

    Abstract translation: 本发明提供含有孕酮的药物口服剂型和相关方法。 口服剂型各自可以包含一定量的孕酮以及药学上可接受的载体。 口服剂型可以配制成具有以下特征中的至少一种：口服剂型产生的孕代谢物平均血浆水平低于约1000nmol / L; 口服剂型产生孕烷代谢物平均血浆水平，施用单次孕酮组合物后，孕妇代谢物水平与母体孕酮水平的比例小于10：1; 当使用USP1型溶出装置在900mL具有2.0％（w / v）月桂基硫酸钠的去离子水中以100rpm进行测量时，其体外溶出速率使得口服剂型释放至少10重量％ 在前30分钟内孕酮的百分比和/或在前4小时内释放小于45重量％ 并且口服剂型产生平均血浆孕酮AUC与施用孕酮量的比例大于1.5×10-6hr / mL：1。

    Progesterone Containing Oral Dosage Forms and Related Methods
    10.
    发明申请
    Progesterone Containing Oral Dosage Forms and Related Methods 审中-公开
    孕激素含有口服剂型及相关方法

    公开(公告)号：US20110312927A1

    公开(公告)日：2011-12-22

    申请号：US12819125

    申请日：2010-06-18

    Applicant: Satish Kumar Nachaegari ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Linus Fonkwe ,  Mahesh Patel ,  Srinivasan Venkateshwaran

    Inventor： Satish Kumar Nachaegari ,  Chandrashekar Giliyar ,  Chidambaram Nachiappan ,  Linus Fonkwe ,  Mahesh Patel ,  Srinivasan Venkateshwaran

    IPC: A61K31/57 ,  A61P15/00 ,  A61P15/08

    CPC classification number: A61K31/57 ,  A61K9/2018 ,  A61K9/2077 ,  A61K9/209 ,  A61K9/2846 ,  A61K9/4808 ,  A61K9/4858

    Abstract: The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood plasma level, after administration of single dose of progesterone composition, such that the ratio of pregnane metabolite level to parent progesterone level of less than 10:1; has a dissolution rate in vitro, when measure using a USP Type-1 dissolution apparatus in 900 mL of deionized water with 2.0% (w/v) of sodium lauryl sulfate at 100 rpm, such that the oral dosage form releases at least 10 wt % of the progesterone within the first 30 minutes and/or releases less than 45 wt % in the first 4 hours; and the oral dosage form produces a ratio of mean plasma progesterone AUC to the amount of progesterone administered of more than 1.5×10−6 hr/mL:1

    Abstract translation: 本发明提供含有孕酮的药物口服剂型和相关方法。 口服剂型各自可以包含一定量的孕酮以及药学上可接受的载体。 口服剂型可以配制成具有以下特征中的至少一种：口服剂型产生的孕代谢物平均血浆水平低于约1000nmol / L; 口服剂型产生孕烷代谢物平均血浆水平，施用单次孕酮组合物后，孕妇代谢物水平与母体孕酮水平的比例小于10：1; 当使用USP1型溶出装置在900mL具有2.0％（w / v）月桂基硫酸钠的去离子水中以100rpm进行测量时，其体外溶出速率使得口服剂型释放至少10重量％ 在前30分钟内孕酮的百分比和/或在前4小时内释放小于45重量％ 并且口服剂型产生平均血浆孕酮AUC与施用孕酮量的比例大于1.5×10-6小时/ mL：1

Patent Agency Ranking